Previous 10 | Next 10 |
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, announced today that it has delivered the 100,000th whole human genome sequence dataset to the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP). Although Personalis h...
Despite Covid-19, Personalis has seen a big jump in its share price while underlying achievements are held back by the virus. I liked the appeal of the business and anecdotal improvements earlier this year (orders) as current numbers do not reflect the real progress being made. Af...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced that the company will participate in the EACR Liquid Biopsies Virtual Event, November 18-19, including a poster presentation and satellite symposia. The company will ...
Multiple companies are working on next-gen blood biopsies tech to detect cancer. The potential market size is big according to most estimates and analysts. Mergers and acquisitions seem to suggest that the era of liquid biopsies has arrived. The frontrunners highlighted in the...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will present data from its clinical test - NeXT Dx TM - at the virtual AMP Annual Meeting from Nov 16-20, 2020. The poster presentation, titled “An exome and transc...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced that the company will participate in the Society for Immunotherapy of Cancer (SITC) Annual Meeting online, November 11-14, including poster presentations on November 11 ...
Personalis, Inc. (PSNL) Q3 2020 Earnings Conference Call November 5, 2020 5:00 PM ET Company Participants Caroline Corner – Investor Relations John West – President and Chief Executive Officer Aaron Tachibana – Chief Financial Officer Conference Call Participants Ivy X. M...
Personalis (PSNL): Q3 GAAP EPS of -$0.27 beats by $0.01.Revenue of $19.8M (+15.5% Y/Y) beats by $0.74M.Shares -4.2% AH.Press Release For further details see: Personalis EPS beats by $0.01, beats on revenue
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today reported financial results for the third quarter ended September 30, 2020. Third Quarter Highlights Reported record revenues of $19.8 million in the third quarter of ...
Lung cancer diagnostics company, Biodesix (BDSX) has priced initial public offering of ~4.17M common shares at $18/share.Underwriters' over-allotment is an additional 600K shares.Trading commences today on Nasdaq.Offering is expected to close on October 30.Net proceeds of ~$30M will be u...
News, Short Squeeze, Breakout and More Instantly...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate virtually at the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on Tuesday, August 13, 2024. About Personalis, Inc. At Personalis, ...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its second quarter 2024 financial results on Wednesday, August 7, 2024. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific...
A look at the top 10 most actives in the United States Serve Robotics Inc. (SERV) rose 187.1% to $7.55 on volume of 255,453,115 shares 60 Degrees Pharmaceuticals Inc. (SXTP) rose 10.2% to $0.271 on volume of 224,640,171 shares NVIDIA Corporation (NVDA) fell 2.6% to $117.93 on volume of 21...